

ASX Announcement

23 November 2020

Antisense Therapeutics dual lists on the Frankfurt Stock Exchange

- Shares commence trading on Frankfurt Stock Exchange;
- Shares trade under FSE code: AWY

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY] is pleased to announce the Company's shares are now dual listed on the Frankfurt Stock Exchange (FSE) with trading commencing Monday 23 November at 8:00AM (CET) under the code AWY.

The dual listing was possible without primary listing procedures and there is no requirement to issue any additional shares due to Company's shares being listed on the ASX, an approved FSE exchange.

Mr. Stefan Müller, the CEO of DGWA (ANP's European representative) said: "DGWA are excited to be partnering with ANP in Europe. Investor interest in mRNA biotechnology in Europe is significant and increasing rapidly. We are optimistic European interest in mRNA technology will translate to ANP which uses its Antisense drugs to target the mRNA of a gene and thereby silence protein expression.

DGWA have a proven and consistent European marketing approach which includes engagement with our extensive database of investors, connections with finance media, German language translation of corporate interviews with CEO, dissemination of ASX releases throughout EU finance channels, engagement with significant biotech investors and family offices in Europe and the UK. We look forward to introducing ANP to our investor networks in Europe and expansion of the company's international investor base".

Mark Diamond, Chief Executive Officer of Antisense Therapeutics said: "Dual listing on the Frankfurt Stock Exchange supports our strategy to broaden overseas investor base in line with the planned clinical development of ATL1102 and our goal of bringing global therapeutic products to global markets".

This announcement has been authorised for release by the Board.

For more information please contact:

Antisense Therapeutics

Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHR production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

About DGWA Deutsche Gesellschaft für Wertpapieranalyse GmbH ("DGWA"), the German Institute for Asset and Equity Allocation and Valuation, is a boutique European investment and financial markets consulting firm based in Frankfurt and Berlin, Germany. The management team have a 25-year track record in trading, investing and analysing SME's around the world. DGWA has been involved in over 250 IPO's, financings, bond issues, dual listings, and corporate finance transactions as well as corresponding road shows and awareness campaigns.